Keratoacanthoma
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Tîpîkî Keratoacanthoma
References
Keratoacanthoma (KA) tîmorek çermê ya pir caran ye ku ji ber mezinbûna xweya bilez û potansiyela xwe ya paşvekêşanê tête zanîn. Ew bi gelemperî di zilamên pîr û çermê xweşik ên ku dîroka zirara tavê heye de pêk tê. Dema ku rakirina neştergerî ya ku bi karanîna jêbirin an neştergeriya mîkrografî ya Mohs dermankirina asayî ye, vebijarkên dermankirinê yên cihêreng hene.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) tumorek nizm e ku di hin rijên çerm de dest pê dike û di binê mîkroskopê de mîna squamous cell carcinoma (SCC) xuya dike. Nîqaşek domdar heye ka gelo KA divê wekî rengek SCC-ya dagirker were dabeş kirin.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) di nav mirovan de, nemaze di nav mirovên pîr de, celebê kanserê duyemîn e. Neştergerî bi gelemperî ji bo dermankirina cSCC tê bikar anîn, lê ji bo hin nexweşên ku nekarin emeliyat bikin an nexwazin, vebijarkên din ên wekî dermankirinên hundurîn têne hesibandin. Tedawiyên kevneşopî yên hundurîn (methotrexate or 5-fluorouracil) hatine bikar anîn, lê lêkolînek domdar li ser nêzîkatiyên nû yên wekî immunoterapiya intralesional û viroterapiya onkolîtîk heye. Li vir, em ê li dermankirinên cûda yên hundurîn ên ji bo cSCC, ji rêbazên klasîk heya stratejiyên pêşkeftî binihêrin.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Di bin mîkroskopê de, keratoacanthoma pir ji nêz ve dişibihe kansera şaneya qermiçî. Digel ku hin patholog keratoacanthoma wekî hebûnek cihêreng û ne nexweşiyek xirab dabeş dikin, bi qasî 6% ji keratoacanthoma klînîkî û histolojîk berbi kansera hucreya squamous a dagirker û êrîşkar pêşve diçin.
○ Nîşanî û dermankirin
#Dermoscopy
#Skin biopsy